Cargando…

Case Report: Evolution of KIT D816V-Positive Systemic Mastocytosis to Myeloid Neoplasm With PDGFRA Rearrangement Responsive to Imatinib

Systemic mastocytosis (SM) is a rare neoplasm resulting from extracutaneous infiltration of clonal mast cells (MC). The clinical features of SM are very heterogenous and treatment should be highly individualized. Up to 40% of all SM cases can be associated with another hematological neoplasm, most f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sciumè, Mariarita, Ceparano, Giusy, Eller-Vainicher, Cristina, Fabris, Sonia, Lonati, Silvia, Croci, Giorgio Alberto, Baldini, Luca, Grifoni, Federica Irene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668610/ https://www.ncbi.nlm.nih.gov/pubmed/34917498 http://dx.doi.org/10.3389/fonc.2021.734025

Ejemplares similares

Target Therapies for Systemic Mastocytosis: An Update
por: Sciumè, Mariarita, et al.
Publicado: (2022)

Complete response of myeloid/lymphoid neoplasms with PDGFRA rearrangement presenting as leukemia/myeloid sarcoma to imatinib monotherapy
por: Ma, Rui, et al.
Publicado: (2019)

Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation
por: Zappulla, Jacques P., et al.
Publicado: (2005)

Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis
por: Naumann, Nicole, et al.
Publicado: (2021)

New Approach to Paediatric Mastocytosis: Implications of KIT D816V Mutation Detection in Peripheral Blood
por: CZARNY, Justyna, et al.
Publicado: (2020)

A case of aggressive systemic mastocytosis with bulky lymphadenopathy showing response to midostaurin
por: Sciumè, Mariarita, et al.
Publicado: (2020)

Successful Imatinib Treatment for Systemic Mastocytosis Associated With Myelodysplastic/Myeloproliferative Neoplasm: Report of a Case and Literature Review
por: Barozzi, Enrico, et al.
Publicado: (2022)

P996: UTILITY OF KIT P.D816 IN MYELOID NEOPLASM WITHOUT DOCUMENTED SYSTEMIC MASTOCYTOSIS TO DETECT HIDDEN MAST CELLS IN BONE MARROW
por: Kim, D. H., et al.
Publicado: (2022)

KIT and PDGFRA Variants and the Survival of Patients with Gastrointestinal Stromal Tumor Treated with Adjuvant Imatinib
por: Joensuu, Heikki
Publicado: (2023)

Imatinib-Associated Tumor Lysis Syndrome in a Patient With Myeloid Neoplasm With Eosinophilia and PDGFRA Rearrangement: A Case Report and Review of the Literature
por: Socola, Francisco, et al.
Publicado: (2017)

Myeloid/lymphoid neoplasm with eosinophilia and rearrangement of PDGFRA presenting as myeloid sarcoma
por: Barouqa, Mohammad, et al.
Publicado: (2022)

Impact of the KIT/PDGFRA genotype on prognosis in imatinib‐naïve Japanese patients with gastrointestinal stromal tumor
por: Cho, Haruhiko, et al.
Publicado: (2021)

Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis
por: Grootens, Jennine, et al.
Publicado: (2019)

Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors
por: Gao, Jing, et al.
Publicado: (2016)

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis
por: Schneeweiss, Mathias, et al.
Publicado: (2018)

KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis
por: Jawhar, Mohamad, et al.
Publicado: (2019)

Eosinophilia in a patient with aggressive systemic mastocytosis harboring a KIT D816V mutation: A case report
por: Cao, Lihong, et al.
Publicado: (2023)

KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
por: Joensuu, Heikki, et al.
Publicado: (2023)

A new humanized in vivo model of KIT D816V(+) advanced systemic mastocytosis monitored using a secreted luciferase
por: Bibi, Siham, et al.
Publicado: (2016)

Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis
por: Lübke, Johannes, et al.
Publicado: (2019)

KIT D816V Mast Cells Derived from Induced Pluripotent Stem Cells Recapitulate Systemic Mastocytosis Transcriptional Profile
por: de Toledo, Marcelo A. S., et al.
Publicado: (2023)

Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis
por: Lyberg, Katarina, et al.
Publicado: (2016)

A tricky and rare cause of pulmonary eosinophilia: myeloid/lymphoid neoplasm with eosinophilia and rearrangement of PDGFRA
por: Zanelli, Magda, et al.
Publicado: (2019)

Continuous diphenhydramine infusion and imatinib for KIT-D816V-negative mast cell activation syndrome: a case report
por: Malik, Faizan, et al.
Publicado: (2017)

Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia
por: Sciumè, Mariarita, et al.
Publicado: (2023)

Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib
por: Kim, Dae Sik, et al.
Publicado: (2018)

Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient
por: Negri, T, et al.
Publicado: (2007)

Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H
por: Revheim, Mona-Elisabeth, et al.
Publicado: (2013)

Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia
por: Kampa-Schittenhelm, Kerstin Maria, et al.
Publicado: (2017)

The spleen microenvironment influences disease transformation in a mouse model of KIT(D816V)-dependent myeloproliferative neoplasm
por: Pelusi, Natalie, et al.
Publicado: (2017)

Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature
por: Alvarez-Twose, Iván, et al.
Publicado: (2016)

Well-differentiated systemic mastocytosis with KIT K509I mutation and uterus infiltration in an Asian woman with good response to imatinib
por: Zhao, Duo-Duo, et al.
Publicado: (2019)

Data on quantification of signaling pathways activated by KIT and PDGFRA mutants
por: Bahlawane, Christelle, et al.
Publicado: (2016)

Morphological Correlates of KIT and PDGFRA Genotypes in Gastrointestinal Stromal Tumour
por: Priya, Valli, et al.
Publicado: (2020)

t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity
por: Mueller, Sarah B., et al.
Publicado: (2022)

Case Report: Pediatric myeloid/lymphoid neoplasm with eosinophilia and PDGFRA rearrangement: The first case presenting as B-lymphoblastic lymphoma
por: Akiely, Reem, et al.
Publicado: (2022)

Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1
por: Tefferi, Ayalew
Publicado: (2009)

Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma
por: Lassus, H, et al.
Publicado: (2004)

Malignant melanoma of the conjunctiva: a case report with examination of KIT and PDGFRA
por: Terada, Tadashi
Publicado: (2012)

Small Cell Carcinoma of the Urinary Bladder: KIT and PDGFRA Gene Mutations
por: Eliyakin, Nuket, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rbpopob8ba5tv8sgd6evjl052g